Rezolute: A Binary Biotech Bet on Breakthrough Hyperinsulinism Therapy with High-Risk and High-Reward Potential
Overview
Rezolute, Inc. is a late-stage biopharmaceutical company specializing in rare metabolic diseases, with a primary focus on hyperinsulinism (HI) conditions causing chronic hypoglycemia. Its lead drug, Ersodetug (RZ358), is in Phase 3 trials for both congenital and tumor-induced HI, aiming to be the first effective chronic therapy in these conditions. The company also develops RZ402, an oral therapy for diabetic macular edema, for which it seeks a partner. Rezolute's addressable market across both HI indications exceeds $1B, shaped by orphan drug dynamics. Its strategic vision is to transform HI care and establish a defensible position in rare pediatric and adult markets, simultaneously seeking to generate revenue through both direct commercialization and external partnerships.